27 – 29 February 2020
Dubai World Trade Centre
For more than 90 years, Lilly Diabetes has been committed to meeting the needs of people affected by diabetes with treatment options, support programs and more. We believe science is most valuable when it is connected to the people who can use it. This belief has inspired Lilly since 1923 when we introduced the world’s first commercial insulin. For more information, visit www.lillydiabetes.com
Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. We are offering one of the broadest portfolios of diabetes products in the industry and are a supplier of nearly half of the world’s insulin with 29.2 million people using its products. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, hemophilia and growth disorders.
Headquartered in Denmark, Novo Nordisk employs approximately 43,200 people in 80 countries and markets its products in more than 170 countries.
Our key contribution is to discover and develop innovative biological medicines and make them accessible to patients throughout the world. We aim to lead in all disease areas in which we are active.
MSD also known as Merck Sharp & Dohme Corp., (a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA) is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, MSD discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. MSD has been present for over than 30 years in the GULF region. MSD GULF operates throughout offices based in the UAE, Kuwait, Bahrain, Qatar & Oman and ranks amongst the leading pharmaceutical companies throughout the GULF region. Through its local distributors, MSD GULF provides innovative medications in several disease entities. These include products for Anti- Infectives, Cardiovascular, Asthma & Allergy, Diabetes, HCV, HIV, Pain & Inflammation, Osteoporosis, Oncology, Fertility, Ophthalmic, and Anesthesia in addition to several specialized Vaccines.
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 105 000 people of more than 140 nationalities work at Novartis around the world. Find out more at www.novartis.com
تعمل نوفارتس للأدوية على تطوير مفهوم الطب والعلاج لتحسين حياة الشعوب وإطالتها. وبوصفها شركة عالمية رائدة في مجال صناعة الأدوية، تستخدم نوفارتس أحدث الابتكارات العلمية والتكنولوجيا الرقمية لتصنيع علاجات قادرة على تحويل حياة الشعوب في المناطق الأشد احتياجًا للدواء. وفي إطار سعينا المتواصل لإيجاد علاجات جديدة، نحتل مكانة متقدمة بين أفضل الشركات العالمية في مجال البحث والتطوير. تصل منتجات نوفارتس إلى حوالي 750 مليون شخص على مستوى العالم، ونسعى للتوصل إلى حلول ابتكارية للتوسع في دعم حصول المرضى على أحدث العلاجات. ويعمل حوالي 105 ألف شخص من أكثر من 140 جنسية في شركة نوفارتس على مستوى العالم. للمزيد من المعلومات، يرجى زيارة موقعنا: www.novartis.com.
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Improving the health of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.
Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of around 17.5 billion euros. R&D expenditure of almost 3.2 billion euros corresponded to 18.1 per cent of net sales.
As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards humankind and the environment.
For more information about Boehringer Ingelheim MEA:
For more than 125 years, Abbott Laboratories has adapted to an increasingly complex healthcare environment by keeping its focus where it belongs—on helping people achieve their best possible health, in all stages of life, around the world.
Abbott has a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and generic pharmaceuticals, serving people in more than 150 countries.
In Diabetes Care, Abbott is constantly improving the glucose monitoring process with diabetes products that are easy to use and highly accurate through innovative product development programs and many cutting-edge glucose monitoring technologies.
For 40 years, Hikma has been developing, manufacturing and marketing branded generic medicines in the MENA region. We supply quality branded generics to 17 markets and have a proven track record with in-licensors. We are also building our injectable medicines business in the territory. Our long-standing presence in the MENA has made us the 5th largest pharmaceutical manufacturer in the region and we have US FDA inspected facilities in Jordan and Saudi Arabia.
As a leading licensing partner globally. Since the early 1980s, we have grown to build a successful track record with global licensing partners. Our partners collaborate with us because of our reputation for quality, our strong brand recognition, and our US FDA inspected manufacturing facilities. Organizations we work with know they can rely on us to deliver consistently, in every market, all over the world.
We're helping to shape a healthier world that enriches all of our communities.
Better health, Within reach, Everyday…
Servier is an international and independent pharmaceutical company governed by a non-profit foundation, with headquarters in Suresnes, France. Since opening our first laboratory in 1954, we have been committed to therapeutic progress to serve patient needs with the help of healthcare professionals. We strive to provide future generations with a world where quality healthcare is available and accessible to all.
Corporate growth at Servier is driven by our continuous pursuit of innovation in five areas of excellence: cardiovascular and immune-inflammatory diseases, neuropsychiatric disorders, cancer and diabetes. We are a leading force in cardiology—number 2 in Europe, number 5 worldwide—and oncology has become a top priority in recent years; we also manufacture high-quality generic drugs.
Our three research centres are continuously involved in creating, testing, and developing new medicinal products, which are manufactured and packaged in our 16 production centres around the world. We have an active partnership policy in the field of biotechnology and we are investing in e-health through our internal WeHealth by Servier initiative.
More information: www.servier.com
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products.
Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.
Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.
For Sponsorship and Exhibition inquiries, please contact firstname.lastname@example.org
Emirates Diabetes & Endocrine Congress (EDEC) is organized by Emirates Diabetes Society. EDEC is the region's premier platform to update attendees on the recent advances in the ever-changing field of diabetes and endocrine diseases.
|MCI Middle East |
United Arab Emirates
Tel: +971 4 311 6300
Fax: +971 4 311 6301